Bridgeway Capital Management, LLC Incyte Corp Transaction History

Bridgeway Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $4,332 - $4,944	-75 Reduced 0.24%	31,800 $1.84 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $4,571 - $5,663	75 Added 0.24%	31,875 $1.98 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $792,724 - $992,498	11,800 Added 59.0%	31,800 $2.55 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $1.32 Million - $1.66 Million	20,000 New	20,000 $1.33 Million
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $4.25 Million - $5.57 Million	-58,200 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $4.28 Million - $5.16 Million	58,200 New	58,200 $4.95 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.